敌对GIPR的行为增加了GLP-1R火焰的火焰
Aaron Novikoff1, Timo D Müller2
1Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Munich, Neuherberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany.
AMG 133是一种新型的双重作用的葡萄糖样-1受体 (GLP-1R) 激动剂和葡萄糖样-1/依赖葡萄糖的胰岛素型多受体 (GIPR) 激动剂,在一期肥胖试验中显示出显著的体重减轻和有利的安全性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 临床试验 临床试验
背景情况:
- 针对GLP-1受体的单分子协激剂在体重管理方面表现有前途.
- 肥胖是一种复杂的代谢障碍,具有重大公共卫生影响.
研究的目的:
- 为了评估AMG 133的安全性,耐受性和有效性,AMG 133是一种双重GLP-1R激动剂/GIPR激动剂,在患有肥胖症的参与者中.
- 评估AMG 133对体重和代谢参数的剂量依赖性影响.
主要方法:
- 进行了1期,随机,双盲,安慰剂控制的临床试验.
- 在特定的治疗期间,参与者接受了不同剂量的AMG 133或安慰剂.
主要成果:
- 在AMG 133中,患者表现出显著且剂量依赖的体重减轻.
- 该药物一般耐受性良好,在剂量组中观察到明显的安全性.
结论:
- AMG 133代表了肥胖症治疗的有前途的治疗候选者.
- 双重GLP-1R激素和GIPR对抗机制需要在更大的临床研究中进一步调查.
更多相关视频
07:30Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
09:16Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells
Published on: April 20, 2017
相关概念视频
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Dipeptidyl Peptidase 4 Inhibitors
GPCRs Regulate Adenylyl Cylase Activity
Oral Hypoglycemic Agents: Glinides
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
GPCR Desensitization
